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The cytokine TNF, especially in combination 
with IFN-, has a very strong antitumor effect. In 
mice, for example, established tumors completely 
regress during 10 d of treatment (Brouckaert 
et al., 1986). In patients, treatment of tumors 
with TNF leads to remarkable results, as in the 
treatment of melanoma metastasis in the limbs 
(Eggermont et al., 2004). However, TNF is a 
very strong inducer of inflammation (Aggarwal 
and Natarajan, 1996). After TNF binds to its 
major receptor TNFR1 (p55), it activates a broad 
range of transcription factors, leading to induc-
tion of cytokines, enzymes, and adhesion mol-
ecules (Kollias et al., 1999). Thus, injection of 
TNF leads to a systemic inflammatory response 
syndrome (SIRS) characterized by hypoten-
sion, hepatitis, and bowel necrosis (Tracey   
et al., 1986; Vassalli et al., 1992). Several mole-
cules have been proven to mediate the acutely 
lethal effects of TNF: IL-1 (Everaerdt et al., 
1994), NO (Cauwels et al., 2000), and, more 
recently, IL-17 (Takahashi et al., 2008). Be-
cause of these strong proinflammatory effects, 
treatment  with  TNF  is  restricted  to  loco- 
regional settings.
Three types of IFNs have been identified: 
type I, type II, and the recently discovered type 
III IFNs (Ank et al., 2006). Type I IFNs form 
a group of almost 20 members, of which IFN- 
is one of the most important. They all signal 
through a heterodimeric receptor complex con-
sisting of an IFN- receptor 1 (IFNAR-1) and 
an IFNAR-2 chain (Uzé et al., 2007). Also, 
type I IFNs have antiviral, apoptotic, and antitu-
mor activities, and they have been shown to 
mediate  the  acute  inflammatory  shock  that 
occurs during endotoxemia (Karaghiosoff et al., 
2003; Mahieu and Libert, 2007).
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Tumor necrosis factor (TNF) is reputed to have very powerful antitumor effects, but it is 
also a strong proinflammatory cytokine. Injection of TNF in humans and mice leads to a 
systemic inflammatory response syndrome with major effects on liver and bowels. TNF is 
also a central mediator in several inflammatory diseases. We report that type I interferons 
(IFNs) are essential mediators of the lethal response to TNF. Mice deficient in the IFN- 
receptor 1 (IFNAR-1) or in IFN- are remarkably resistant to TNF-induced hypothermia 
and death. After TNF injection, IFNAR-1/ mice produced less IL-6, had less bowel dam-
age, and had less apoptosis of enterocytes and hepatocytes compared with wild-type (WT) 
mice. Extensive gene expression analysis in livers of WT and IFNAR-1/ mice revealed a 
large deficiency in the response to TNF in the knockout mice, especially of IFN-stimulated 
response element–dependent genes, many of which encode chemokines. In livers of IFNAR-
1/ mice, fewer infiltrating white blood cells (WBCs) were detected by immunohistochem-
istry. Deficiency of type I IFN signaling provided sufficient protection for potentially safer 
therapeutic use of TNF in tumor-bearing mice. Our data illustrate that type I IFNs act as 
essential mediators in TNF-induced lethal inflammatory shock, possibly by enhancing cell 
death and inducing chemokines and WBC infiltration in tissues.
© 2009 Huys et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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indicate that this TNF effect is enhanced by type I IFNs. The 
apoptosis-enhancing  activity  of  type  I  IFN  was  recently 
shown for macrophages as well (Qiu et al., 2008). Further-
more, type I IFNs have been shown to exert apoptotic effects 
on renal epithelial cells (Lechner et al., 2008). TNF not only 
induces  apoptosis  of  enterocytes,  it  also  induces  multiple 
mechanisms through the death receptor pathway to initiate 
hepatocyte apoptosis leading to liver injury (Ding and Yin, 
2004). Liver injury has been identified as a major dose-limiting 
toxicity of TNF. We therefore compared the degree of acute 
enterocyte apoptosis and liver damage after TNF injection in 
WT  and  IFNAR-1/  mice  by  several  techniques.  Mice 
were injected with 30 µg TNF, and the degree of apoptosis 
was estimated in bowels and livers 1 and 6 h after injection 
by measuring the extent of DNA fragmentation, caspase 
3/caspase 7 activity, and TUNEL staining. As shown in Fig. 3 A, 
the extent of DNA fragmentation induced by TNF was very 
high in intestines 1 h after challenge and in liver 6 h after 
challenge, but it was significantly less in IFNAR-1/ mice 
than in WT mice (P = 0.03986 and P = 0.0313, respectively). 
A  similar  pattern  was  observed  when  studying  caspase   
3/caspase 7 activity in TNF-injected mice (Fig. 3 B) or when 
staining sections for TUNEL activity (not depicted).
We conclude that abolition of type I IFN signaling protects 
mice against the acute inflammatory and toxic effects of TNF. 
The protective effect is initiated early and is reflected in the 
lower degree of hypothermia and lower level of circulating IL-6, 
as well as in reduced enterocyte and liver apoptosis, which are 
the major dose-limiting toxicities of TNF (Tracey et al., 1986).
Reduced expression of genes after TNF injection  
in IFNAR-1/ mice
Very moderate induction of the major type I IFN (IFN-) by 
TNF  was  recently  shown  in  macrophages  (Yaralina  et  al., 
2008). Because the liver has been reported as a major target for 
TNF (Wielockx et al., 2001), we studied the levels of IFN- 
messenger RNA in livers by quantitative PCR and found a 
sharp but transient induction in WT mice and a slow gradual 
increase in IFNAR-1/ mice (Fig. 4 A). The late appear-
ance of IFN- at the RNA level after injection of TNF in 
IFNAR-1/ mice might be, as has been proposed previ-
ously (Fenner et al., 2006), the result of weaker induction of 
inhibitors of the Jak–Stat pathway, such as SOCS molecules, 
by IFN-. It should be noted that no IFN activity could be 
measured in serum or liver extract of TNF-injected mice by 
IFN-–specific ELISA or by a sensitive bioassay based on the 
antiviral activity of IFN.
To study the effects of IFNAR-1 deletion on TNF-induced 
gene expression in vivo, we measured the expression of several 
genes in the liver and spleen 0, 2, 6, and 10 h after injection of 
30 µg TNF. In both the liver and spleen, the expression of all 
studied genes was compromised in IFNAR-1/ mice. When 
we examined the induction of early genes by TNF, the large 
difference in induction of IRF-1 was remarkable (Fig. 4 B). 
The induction of other genes that depend on NF-B, such as 
those coding for inducible nitric oxide synthase (iNOS), IL-1, 
It was recently shown that TNF stimulates the expression of 
type I IFNs through IRF-1 in macrophages and, via IFNAR-1, 
the expression of IFN-stimulated response element (ISRE)–
dependent genes (Yarilina et al., 2008). We therefore won-
dered whether type I IFNs play a role in the TNF-induced 
acutely lethal SIRS. Our data clearly support the idea that 
type I IFNs are strong mediators of the in vivo TNF effects and 
that their inhibition could lead to safer antitumor therapy based 
on TNF.
RESULTS AND DISCUSSION
IFNAR-1/ mice and IFN-/ mice are protected against 
TNF-induced lethal SIRS
We studied the role of type I IFNs by using IFNAR-1/ 
mice, IFN-/ mice, and WT mice. All mice had a matching 
genetic background of C57BL/6. IFNAR-1/ and WT 
mice were injected i.p. with 30 µg of recombinant mouse 
TNF (2xLD100 for WT mice) and mortality was recorded 
during 72 h, after which no further deaths occurred. All WT 
mice  died,  whereas  all  IFNAR-1/  mice  survived  (P  < 
0.0001; Fig. 1 A). Moreover, although IFNAR-1/ mice 
displayed a mild and transient hypothermia, WT mice suf-
fered pronounced hypothermia before dying (Fig. 1 B). In 
another experiment, 24 mice per genotype were injected i.p. 
with 30 µg TNF, and groups of six WT and six IFNAR-1/ 
mice were bled at different times to study the induction pro-
file of IL-6. Although this cytokine is functionally inert in 
this TNF model, its induction profile illustrates the extent of 
gene induction (Libert et al., 1994) and inflammation. As can 
be seen in Fig. 1 C, basal serum levels of IL-6 were comparable 
in WT and IFNAR-1/ mice, but 2, 6, and 10 h after TNF 
challenge, the increase in IL-6 serum concentrations was signifi-
cantly more pronounced in WT than in IFNAR-1/ mice. 
It is notable that the difference from the WT developed rela-
tively quickly. Furthermore, serum concentrations of IL-12p40 
and IL-12p70 were also much lower in IFNAR-1/ mice 6 
h after challenge (unpublished data). Because we found 
that our IFNAR-1/ mice displayed a mild reduction in the 
numbers of NK and NKT cells in liver but not in spleen (un-
published data), we also tested the response of IFN-/ 
mice to TNF. These mice were also significantly resistant to 
the lethal effects of TNF (P = 0.0027) and to hypothermia 
(Fig. 1, D and E).
Sections of the small intestines (ileum) were made 1 and 
6 h after challenge and stained with hematoxylin/eosin. As 
early as 1 h after challenge, the detrimental effect of TNF was 
much less pronounced in the IFNAR-1/ mice than in WT 
mice. We observed less shrinkage and erosion of villi, less 
mucus formation, fewer apoptotic nuclei, and milder loss of 
Goblet cells (Fig. 2 A). The degree of tissue damage in these 
sections was quantified using the method described by Halpern 
et al. (2003). Significantly less damage was induced by TNF 
in IFNAR1/ than in WT mice 1 and 6 h after challenge 
(P = 0.0255 and P = 0.0046, respectively; Fig. 2 B).
Acute cell death (apoptosis) of enterocytes after TNF in-
jection has been reported (Piguet et al., 1998), and our data JEM VOL. 206, August 31, 2009  1875
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Figure 1.  IFNAR-1/ mice and IFN-/ mice are resistant to TNF-induced shock. 30 µg TNF was injected i.p. in WT (n = 14) and IFNAR-1/  
(n = 14) mice. (A) Mortality was monitored for 72 h (no further deaths occurred). (B) Body temperatures were measured regularly and plotted in function 
of time. (C) New groups of WT (black) and IFNAR-1/ (gray) mice (n = 44 in total) were injected with 30 µg TNF i.p. and bled for IL-6 determination. IL-6 
values are expressed on a log scale. 17.5 µg TNF was injected i.p. in WT (n = 12) and IFN-/ (n = 12) mice. (D) Mortality was monitored for 72 h (no 
further deaths occurred). (E) Body temperatures were measured regularly and plotted as a function of time. Experiments in A–C were performed three 
times; D and E were performed twice. Error bars represent SD of the means. *, 0.01 ≤ P ≤ 0.05; **, 0.001 ≤ P ≤ 0.01; ***, P ≤ 0.001.1876 IFNAR-1 IN TNF-INDUCED SHOCK | Huys et al.
When comparing the induction of later Jak–Stat-dependent 
genes, the expression in the IFNAR-1/ mice was again 
found to be greatly reduced. The genes encoding CXCL9, 
CXCL10, CXCL11, IFIT2, STAT1, and IRF-7 were induced 
by TNF in the liver of WT mice but to a much smaller extent 
(or not at all) in the absence of the IFNAR-1 receptor (Fig. 
4, F–K). These genes belong to the group of ISRE genes, the 
promoters of which are controlled by the transcription complex 
ISGF3. This complex consists of STAT-1–STAT-2–IRF-9 
and c-Flip, was also substantially compromised in IFNAR-1/ 
mice, especially at the early time point (Fig. 4, C–E). This can 
be explained, at least for the iNOS and IL-1 genes, by their 
coregulation by NF-B and IRF factors and also in the pro-
moter of the c-Flip-encoding gene because NF-B, as well as 
IRF-responsive elements, was found by using the bioinformat-
ics program Contra (not depicted; Hooghe et al., 2008). The 
lower level of serum IL-12 can also be explained by this 
reduced expression of IRF-1 (Liu et al., 2004).
Figure 2.  Bowel damage after TNF injection in WT mice and IFNAR-1/ mice. (A) IFNAR-1/ mice are protected against TNF-induced bowel 
tissue destruction. 30 µg TNF was injected i.p. in WT mice (n = 18) and IFNAR-1/ mice (n = 18), and jejunum was sampled 0 h (n = 6), 1 h (n = 6), and 6 h 
(n = 6) later. Standard hematoxylin/eosin staining of control samples (left), 1 h (middle), and 6 h (right) after TNF injection showed more extensive tissue 
damage in the bowel of WT mice (top) than in IFNAR-1/ mice (bottom). Bars, 50 µm. The experiment was performed twice. (B) Neutral observers quan-
tified the degree of bowel toxicity in sections from an independent experiment. The experiment was analogous to the one in A but used 19 WT mice and 
18 IFNAR-1/ mice. Error bars represent SD of the means. *, 0.01 ≤ P ≤ 0.05; **, 0.001 ≤ P ≤ 0.01.JEM VOL. 206, August 31, 2009  1877
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the blood stream into the tissue to cause further damage. 
Therefore, we injected mice i.p. with 30 µg TNF and sam-
pled livers 6 h later. We also took samples from untreated 
mice. Tissue sections were stained for several WBC markers, 
namely the general WBC marker CD45, the T cell marker 
CD3, the marker for polymorphonuclear cells and mono-
cytes MPO, and F4/80, a marker of macrophages (Fig. 5). 
The numbers of positive cells in WT and IFNAR-1/ mice 
were compared. In the liver, we found that the numbers 
of WBC in the parenchyma were significantly lower in 
IFNAR1-1/ mice whether they were CD3, CD45, MPO, 
or F4/80 positive. It is noteworthy that WBCs in IFNAR-1/ 
mice seemed to accumulate in veins and arteries, whereas in 
WT mice they crossed the endothelial barrier into the paren-
chyma. Because CXCL9, CXCL10, and CXCL11 bind to 
heterotrimers and is formed after stimulation of the IFNAR 
receptor (Maher et al., 2007). Most ISRE genes have im-
mune modulatory, antiviral, or chemotactic functions (Der 
et al., 1998). Deficient induction of a whole set of chemo-
kines, such as CXCL9, CXCL10, CXCL11, and IFIT2, should 
have profound effects on the chemotaxis of white blood cells 
(WBCs) in vivo.
Reduced infiltration of WBC in IFNAR-1/ mice
Because the induction of several chemokines upon TNF 
injection seemed much weaker (or altogether absent) in livers 
of IFNAR-1/ mice compared with WT mice, we investi-
gated whether infiltration of tissues by WBCs was reduced. 
Indeed, stimulation of the IFNAR-1 receptor in WT mice is 
expected to produce chemokines, which attract WBC from 
Figure 3.  TNF induces less apoptosis in IFNAR-1/ mice than in WT mice. 30 µg TNF was injected i.p. in WT mice and IFNAR-1/ mice, and 
jejunum and liver were sampled 0 h (n = 7–8), 1 h (n = 7–8), and 6 h (n = 8) later. (A) The degree of DNA fragmentation was measured and expressed as 
an enrichment factor compared with the 0-h values. (B) The sum of the activities of caspase 3 and caspase 7 was determined and expressed in relative 
luminescence units (RLU). The entire experiment was performed twice. Error bars represent SD of the means. *, 0.01 ≤ P ≤ 0.05; **, 0.001 ≤ P ≤ 0.01.1878 IFNAR-1 IN TNF-INDUCED SHOCK | Huys et al.
well. We studied this possibility in a standard tumor model. 
We inoculated 19 WT and 20 IFNAR-1/ mice with 6 × 105 
B16BL6 melanoma cells in the right thigh. 10 d later, tumors 
in IFNAR-1/ mice had grown slightly larger than in WT 
mice (Fig. 6 A). This confirms earlier findings and illustrates 
that type I IFNs have some antiproliferative activity (Li et al., 
2008). The mice were then divided into four groups and in-
jected near the lesions with PBS or with 15 µg TNF + 5,000 
the rather generally expressed receptor CxCR3 on WBCs, 
the reduced infiltration of CD3-, CD45-, MPO-, and F4/80-
positive cells can be explained.
Safer antitumor therapy with TNF/IFN- in IFNAR-1/ mice
The protection provided by knockout of IFNAR-1 against 
acute lethal SIRS induced by a bolus injection of TNF raises 
hopes that it might be protective in an antitumor model as 
Figure 4.  TNF-induced gene expression in liver is lower in IFNAR-1/ mice than in WT mice. WT (n = 4; black) and IFNAR-1/ (n = 4; gray) 
mice were injected with 30 µg TNF i.p. and RNA was isolated 0, 1, 2, 6, and 10 h after injection. Quantitative PCR was used to measure gene-specific RNA 
levels of a set of early genes encoding IFN- (A), IRF-1 (B), iNOS (C), IL-1 (D), and c-FLIP (E), as well as ISRE genes encoding CXCL9 (F), CXCL10 (G), 
CXCL11 (H), IFIT2 (I), STAT1 (J), and IRF-7 (K). The experiment was performed twice. Error bars represent SD of the means. *, 0.01 ≤ P ≤ 0.05; **, 0.001 ≤ P ≤ 
0.01; ***, P ≤ 0.001.JEM VOL. 206, August 31, 2009  1879
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I IFNs are also involved in other TNF-induced or TNF-
mediated pathologies such as arthritis. Yarilina et al. (2008) 
found that TNF in macrophages induces a typical type   
I IFN program through IRF-1 and that IFN- was ele-
vated  in  synovial  fluids  of  arthritic  patients.  Therefore, 
therapeutic inhibition of type I IFNs is conceivable. The 
endogenous type I IFNs, however, are crucial for antiviral 
defences,  and  IFNAR-1/  mice  are  hypersensitive  to 
many viral infections. Hence, although therapeutic inhibi-
tion of type I IFNs in inflammatory conditions seems logical, 
it is difficult to achieve in practice.
In conclusion, deficiency of type I IFNs in vivo leads to 
considerable  protection  against  the  deleterious  effects  of 
TNF. Two mechanisms might be involved in this protec-
tion. Type I IFNs seem to enhance TNF-induced apoptosis 
in enterocytes and hepatocytes. In contrast, deficient induc-
tion of chemokine genes is observed and is reflected in re-
duced infiltration of inflammatory cells in mice deficient in 
type I IFN receptor. Therapeutic inhibition of this family of 
IFNs  should  be  evaluated  for  treatment  of  disorders  in 
which TNF is implicated or for increasing the therapeutic 
index of TNF in cancer therapy. The safety of therapeutic 
IU IFN- per mouse per day. Daily measurement of tumor 
index showed that tumors regressed equally in WT (n = 10) 
and IFNAR-1/ mice (n = 10; Fig. 6 B). All 10 WT mice 
and only 2 out of 10 IFNAR-1/ mice died from the treat-
ment (P = 0.0003; Fig. 6 C). This illustrates that type I IFNs 
also mediate much of the toxicity associated with the anticancer 
activity of TNF/IFN-.
Many patients have been treated with type I IFNs for 
cancer, multiple sclerosis, and viral infections such as HBV 
and HCV (Maher et al., 2007). Although these patients 
suffer from severe side effects of the treatment, no serious 
accidents have been reported. However, although type I 
IFNs have been shown to possess some antiinflammatory 
activities, especially in the central nervous system, several 
authors  have  shown  that  they  should  be  considered  as   
important  mediators  in  acute  inflammatory  conditions. 
Absence of IFN- or IFNAR-1 in knockout mice leads   
to complete protection against LPS-induced lethal inflamma-
tory shock (Karaghiosoff et al., 2003; Mahieu and Libert, 
2007). In our study, we found that the presence or absence 
of type I IFN signaling also has a large impact on the out-
come of TNF-induced inflammation. We expect that type 
Figure 5.  Reduced tissue migration of WBC in IFNAR-1/ mice after injection with TNF. WT (n = 6) and IFNAR-1/ (n = 6) mice were injected 
i.p. with 30 µg TNF and livers were isolated 0 or 6 h later. Sections were cut and stained with CD45, CD3, MPO, and F4/80. Five representative fields were 
selected in all samples and the mean number of positive cells in five fields at 40× was counted by a neutral observer. Bars, 50 µm. IHC was performed 
three times. Error bars represent SD of the means. *, 0.01 ≤ P ≤ 0.05; **, 0.001 ≤ P ≤ 0.01; ***, P ≤ 0.001.1880 IFNAR-1 IN TNF-INDUCED SHOCK | Huys et al.
MATERIALS AND METHODS
Mice. C57BL/6J WT mice were purchased from Charles River Laborato-
ries. IFNAR-1 knockout mice (IFNAR-1/) and IFN- knockout mice 
(IFN- /), both with a C57BL/6J genetic background, were provided by 
D. Bonaparte (Gulbenkian Institute of Science, Oeiras, Portugal) and   
S. Weiss, respectively. The mice were kept in individually ventilated cages 
in a conventional animal house and were used at the age of 8–12 wk. Animal 
studies were approved by the ethics committee of Ghent University.
Agents. Recombinant mouse TNF and IFN- were produced in Escherichia 
coli and purified to homogeneity in our laboratories. TNF and IFN- had 
specific activities of 1.2 × 108 IU/mg and 1.16 × 107 IU/mg, respectively, 
with no detectable endotoxin contamination.
Injections, monitoring, and sampling. TNF was diluted in endotoxin-
free PBS and injected i.p. in a volume of 0.2 ml. Mortality was scored for 72 h. 
Serum and tissue samples were collected 0, 1, 2, 6, and 10 h after injection. 
Blood was withdrawn by cardiac puncture and allowed to clot overnight 
at 4°C. The clot was removed, and serum was collected after centrifugation 
at 20,000 g for 10 min and stored at 20°C. Tissue samples were fixed briefly 
and embedded in paraffin by a standard protocol (Tissue-Tek VIP; Sakura). 
RNA samples were isolated by using RNeasy (QIAGEN).
Tumor cell culture and inoculation. B16BL6 cells were cultured in 
DME supplemented with fetal calf serum, antibiotics, and  l-glutamine. Cells 
were harvested, washed three times in LPS-free PBS, and brought to a den-
sity of 6 × 106/ml. From this cell suspension, 100 µl was injected s.c. into the 
right hind limbs of the mice.
Tumor size index (TSI) and body temperature. The smaller and larger 
diameters of the tumors were measured with an electronic caliper, and TSI 
was calculated by multiplying these two values. Rectal body temperature 
was measured with an electronic thermometer (model 2001; Comark).
Determination of IL-6 and IFN-. IL-6 was determined in serum as 
previously described (Van Snick et al., 1986). Levels of IFN- in serum and 
in liver extracts were determined by an ELISA system (PBL Biomedical 
Laboratories) according to the manufacturer’s instructions. The sensitivities 
of the IL-6 assay and the ELISA kit were 1 and 10 pg/ml, respectively.
Tissue section and histology. Tissue sections of 4 µm were cut and 
stained with hematoxylin/eosin using standard techniques. After staining, 
the codes on the bowel sections were blinded and tissue damage was quanti-
fied with four neutral observers using the necrotizing enterocolitis scoring 
system published and validated by Halpern et al. (2003). The mean value of 
their estimations was used.
Immunohistochemistry (IHC). 4-µm liver sections were deparaffinized 
for  antigen  retrieval  followed  by  rehydration.  CD45  (Trowbridge  and 
Thomas, 1994), CD3 (Haniffa et al., 2007), and MPO (Pinkus and Pinkus, 
1991) IHC used target retrieval solution (Dako) or proteinase K treatment 
(10 µg/ml; Promega) in proteinase K buffer (100 mM Tris-HCl, pH 8.0, and 
50 mM EDTA; for F4/80; van den Berg and Kraal, 2005), blocking in rabbit 
or swine serum (Dako), peroxidase blocking buffer (Dako), and incubation 
with anti-CD45 (BD), anti-CD3 (Abcam), anti-MPO (Dako), and anti-F4/80 
(AbD Serotec) antibodies. Biotin-conjugated IgGs (Dako), the Vectastain 
ABC kit (Vector Laboratories), and AEC (Dako) were used for visualization. 
The slides were counterstained with hematoxylin solution (Sigma-Aldrich). 
CD45-, CD3-, MPO-, and F4/80-positive cells were counted in five ran-
dom 40× fields in a double-blinded fashion. Negative controls were made by 
substituting buffer for primary antibody.
Real-time PCR. RNA samples were reverse transcribed using oligo (dT) 
primers  and  MMLV  reverse  transcription.  Primers  were  designed  with 
Primer Express (Applied Biosystems) and purchased from Biolegio. Quantitative 
inhibition with anti–type I IFN agents should be evaluated 
because these IFNs possess essential antiviral activities (Müller 
et al., 1994).
Figure 6.  Protection of tumor-bearing IFNAR-1/ mice against 
TNF/IFN- lethality. WT (n = 19; ) and IFNAR-1/ (n = 20; ) mice 
were inoculated with B16BL6 melanoma cells. 10 d later, tumors were 
measured, TSI was calculated (A), and treatment was started. Treatment 
was daily for 10 d with PBS (black lines) in 9 WT and 10 IFNAR-1/ mice 
or with TNF/IFN- (red) in 10 WT and 10 IFNAR-1/ mice. Tumor regres-
sion (B) and mouse survival (C) were recorded until the end of the treat-
ment (no further deaths occurred). The difference in survival between WT 
(n = 10) and IFNAR-1/ (n = 10) mice was highly significant. The experi-
ment was performed twice. Error bars represent SD of the means. *, 0.01 ≤ 
P ≤ 0.05; ***, P ≤ 0.001.JEM VOL. 206, August 31, 2009  1881
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